Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide.
The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI. However, the response to a given dose was discrepant between both studies.
Phase III studies for MS started in December 2007. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce relapses into MS among patients beyond a placebo. However, the final results of above-mentioned phase III trial proved oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.
^Tan IL, Lycklama à Nijeholt GJ, Polman CH et al. (April 2000). "Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials". Mult Scler6 (2): 99–104. doi:10.1191/135245800678827626. PMID10773855.
^Comi G, Pulizzi A, Rovaris M et al. (June 2008). "Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study". Lancet371 (9630): 2085–2092. doi:10.1016/S0140-6736(08)60918-6. PMID18572078.
^Kresege, Naomi (1 August 2011). "Teva’s Copaxone Successor Fails in Latest Clinical Trial". Bloomberg. Retrieved 2 August 2011. Teva Pharmaceutical Industries Ltd. (TEVA)’s experimental multiple sclerosis pill failed to reduce relapses more than placebo in a clinical trial, dealing a blow to the company’s effort to find a successor to an older drug.
^Comi, G.; Jeffery, D.; Kappos, L.; Montalban, X.; Boyko, A.; Rocca, M. A.; Filippi, M.; Allegro Study, G. (2012). "Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis". New England Journal of Medicine366 (11): 1000–1009. doi:10.1056/NEJMoa1104318. PMID22417253.edit